IHMT-PI3Kδ-372

IHMT-PI3Kδ-372 is a potent and selective PI3Kδ inhibitor with an IC50 of 14 nM. IHMT-PI3Kδ-372 shows high selectivity over other class I PI3Ks (56～83 fold) and other protein kinases. IHMT-PI3Kδ-372 can be uesd for chronic obstructive pulmonary disease (COPD) research[1].

Product Specifications

CAS Number

[2429889-61-0]

UNSPSC

12352005

Target

Cytochrome P450; PI3K

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease; PI3K/Akt/mTOR

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/ihmt-pi3kδ-372.html

Concentration

10mM

Purity

99.69

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C1N(C2CC2)C([C@@H](N3N=C(C4=CC=C(OC)C(F)=C4)C5=C(N)N=CN=C53)CC)=NC6=C1C(F)=CC=C6

Molecular Formula

C26H23F2N7O2

Molecular Weight

503.50

References & Citations

[1]Feng Li, et al. Discovery of (S) -2- (1- (4-Amino-3- (3-fluoro-4-methoxyphenyl) -1 H-pyrazolo[3,4- d]pyrimidin-1-yl) propyl) -3-cyclopropyl-5-fluoroquinazolin-4 (3 H) -one (IHMT-PI3Kδ-372) as a Potent and Selective PI3Kδ Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease. J Med Chem. 2020 Nov 25;63 (22) :13973-13993.